1. Home
  2. GATX vs MIRM Comparison

GATX vs MIRM Comparison

Compare GATX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GATX Corporation

GATX

GATX Corporation

HOLD

Current Price

$179.60

Market Cap

6.1B

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$114.94

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GATX
MIRM
Founded
1898
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1B
5.7B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
GATX
MIRM
Price
$179.60
$114.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
13
Target Price
$215.50
$119.85
AVG Volume (30 Days)
202.2K
727.0K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
1.36%
N/A
EPS Growth
17.22
74.59
EPS
2.35
N/A
Revenue
$1,740,400,000.00
$19,138,000.00
Revenue This Year
$42.21
$26.22
Revenue Next Year
$3.35
$22.04
P/E Ratio
$75.73
N/A
Revenue Growth
9.77
N/A
52 Week Low
$148.20
$47.89
52 Week High
$205.56
$114.99

Technical Indicators

Market Signals
Indicator
GATX
MIRM
Relative Strength Index (RSI) 54.44 72.95
Support Level $166.31 $87.93
Resistance Level $186.61 $114.99
Average True Range (ATR) 3.88 4.26
MACD 1.34 1.94
Stochastic Oscillator 83.57 94.33

Price Performance

Historical Comparison
GATX
MIRM

About GATX GATX Corporation

GATX Corp leases transportation assets, including railcars, aircraft spare engines, and tank containers, to customers in North America, Europe, and India. The company's reportable business segments are: Rail North America, Rail International, Engine Leasing, and Other. The majority of its revenue is generated from the Rail North America segment, which is composed of the company's operations in the United States, Canada, and Mexico. This segment mainly provides railcars pursuant to full-service leases under which it maintains the railcars, pays ad valorem taxes and insurance, and provides other ancillary services.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Share on Social Networks: